666. Outcomes Using Cefiderocol for the Treatment of Acinetobacter baumannii Infections from the PROVE (Real-World Evidence) Study

BACKGROUND: PROVE is an ongoing international, retrospective study assessing cefiderocol (CFDC) for Gram-negative (GN) infections. Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are difficult-to-treat with limited treatment options. CFDC is a novel sidero cephalosporin with activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcella, Stephen, Kobic, Emir, Carr, Amy L, Georgiades, Benjamin, Margiotta, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752166/
http://dx.doi.org/10.1093/ofid/ofac492.718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752166/
http://dx.doi.org/10.1093/ofid/ofac492.718

Ejemplares similares